Weekly subcutaneous alemtuzumab and rituximab for relapsed CLL [chronic lymphocytic leukaemia].

Trial Profile

Weekly subcutaneous alemtuzumab and rituximab for relapsed CLL [chronic lymphocytic leukaemia].

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 May 2016 Status changed from active, no longer recruiting to completed.
    • 30 Nov 2012 Planned End Date changed from 1 Jul 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top